LEADER 01127cam0-2200349---450- 001 990004046160403321 005 20090312101611.0 035 $a000404616 035 $aFED01000404616 035 $a(Aleph)000404616FED01 035 $a000404616 100 $a19990604d1985----km-y0itay50------ba 101 1 $aita$cger 102 $aIT 105 $ay-------001yy 200 1 $a<>avventura cavalleresca$eideale e realtà nei poemi della Tavola Rotonda$fErich Köhler 210 $aBologna$cIl Mulino$d1985 215 $aXXXVI, 369 p.$d21 cm 225 1 $aCollezione di testi e di studi$iLinguistica e critica letteraria 454 0$12001$aIdeal und Wirklichkeit in der höfischen Epik$912522 610 0 $aRomanzi cavallereschi francesi$aSec. 12.-13. 676 $a841.109 700 1$aKöhler,$bErich$f<1924-1981>$0394035 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990004046160403321 952 $a841.109 KOH 1$bDip.f.m.1280$fFLFBC 952 $aF.Russo 445$fBAT 959 $aFLFBC 959 $aBAT 996 $aIdeal und Wirklichkeit in der höfischen Epik$912522 997 $aUNINA LEADER 03316nam 2200961z- 450 001 9910557610103321 005 20231214133507.0 035 $a(CKB)5400000000045301 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/79654 035 $a(EXLCZ)995400000000045301 100 $a20202203d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPharmacogenetics to Avoid Adverse Drug Reactions 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (220 p.) 311 $a3-0365-3344-3 311 $a3-0365-3343-5 330 $aAdverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics. 606 $aMedicine$2bicssc 610 $a5-fluorouracil 610 $acapecitabine 610 $afluoropyrimidine 610 $athymidylate synthase 610 $athymidylate synthase enhancer region 610 $aupstream stimulatory factor 1 610 $aadverse drug reactions 610 $apharmacogenomics 610 $aepistasis 610 $arandom forest 610 $astatin 610 $acardiovascular disease 610 $acolorectal cancer 610 $apersonalised medicine 610 $atoxicity 610 $a(es)citalopram 610 $adrug-gene-interaction 610 $adrug-drug-interaction 610 $adrug-drug-gene-interaction 610 $athe PharmLines initiative 610 $aantipsychotic agents 610 $apharmacogenetics 610 $acytochrome P-450 enzyme system 610 $apsychotic disorders 610 $aprecision medicine 610 $adirect oral anticoagulants 610 $aclinical implementation 610 $aatorvastatin 610 $aSLCO1B1 610 $aHLA 610 $acutaneous adverse drug reaction 610 $aSCAR 610 $agenetic polymorphism 610 $aantiepileptics 610 $aCYP450 enzymes 610 $aplatelet reactivity 610 $asingle-nucleotide variants 610 $aacute coronary syndrome 610 $aclopidogrel 610 $agenotype 610 $aallele 610 $apolymorphism 610 $aHLA B 610 $aCYP2C9*3 610 $acutaneous adverse drug reactions (CADRs) 610 $aanti-epileptic drugs (AEDS) 610 $aphenytoin (PHT) 610 $agenetic risk factors 610 $aSouth India 610 $aIndia 610 $acardiology 610 $aadverse events 610 $aguidelines 615 7$aMedicine 700 $aLo?pez-Ferna?ndez$b Luis A$4edt$01319399 702 $aLo?pez-Ferna?ndez$b Luis A$4oth 906 $aBOOK 912 $a9910557610103321 996 $aPharmacogenetics to Avoid Adverse Drug Reactions$93033877 997 $aUNINA